WorldPharmaNews
  • Home
  • Business
  • Research
  • Events
  • Regulatory

Daiichi Sankyo

Daiichi SankyoDaiichi Sankyo Group is dedicated to the creation and supply of innovative pharmaceutical products to address diversified, unmet medical needs of patients in both mature and emerging markets. With over 100 years of scientific expertise and a presence in more than 20 countries, Daiichi Sankyo and its 17,000 employees around the world draw upon a rich legacy of innovation and a robust pipeline of promising new medicines to help people. In addition to its strong portfolio of medicines for hypertension, dyslipidemia, bacterial infections, and thrombotic disorders, the Group’s research and development is focused on bringing forth novel therapies in cardiovascular-metabolic diseases, pain management, and oncology, including biologics.

www.daiichisankyo.com.

Daiichi Sankyo RSS Channel

Filters
List of articles in category Daiichi Sankyo
Title Published Date
Daiichi Sankyo announces TaNeDS Global 2018 collaborative drug discovery program 26 September 2017
Daiichi Sankyo announces collaborative research on drugs for neglected tropical diseases 30 March 2017
Daiichi Sankyo announces TaNeDS Europe 2017 collaborative drug discovery programme 12 October 2016
Amgen and Daiichi Sankyo announce agreement to commercialize biosimilars in Japan 14 July 2016
Daiichi Sankyo announces commencement of clinical trials in Japan for Duchenne muscular dystrophy treatment 25 February 2016
Daiichi Sankyo signs agreement with Translational Sciences, Inc. to develop and commercialize the first-in-class thrombus dissolving agent, TS23 22 September 2015
Daiichi Sankyo and Ranbaxy launch hybrid business in Brazil to expand business of both companies 17 April 2013
Daiichi Sankyo Establishes New Vaccine Research Unit in Japan 01 November 2011
Daiichi Sankyo & Ranbaxy Announce a New Social Contribution Initiative 31 August 2011
Daiichi Sankyo and Ranbaxy to Integrate New Drug Research and Development System 05 July 2010
Ranbaxy Launches Antiplatelet Agent Prasugrel in India 10 June 2010
Daiichi Sankyo and Lilly Receive U.S. FDA Approval for Effient™ 13 July 2009
DAIICHI SANKYO continues its expansion in Germany and Europe 21 August 2008
DAIICHI SANKYO acquires osteoporosis medication EVISTA® from Lilly 07 March 2008

Business & Industry

  • GSK completes acquisition of Sierra Oncology
  • Pfizer and BioNTech announce new agreement with U.S. government to provide additional doses of COVID-19 vaccine
  • Bayer opens new Research & Innovation Center in Boston-Cambridge demonstrating its commitment to precision oncology
  • New Novartis extension phase data show nearly 80% of RMS patients treated with Kesimpta® (ofatumumab) had no evidence of disease activity (NEDA-3)
  • Pfizer and BioNTech announce Omicron-adapted COVID-19 vaccine candidates demonstrate high immune response against Omicron

Research & Development

  • Inhalable COVID-19 vaccine shows promise in rodent model
  • Researchers discover new leukemia-killing compounds
  • Oral antiviral drug effective against respiratory syncytial virus (RSV) identified by researchers
  • Biomarkers found that could be drug targets against a deadly form of brain cancer
  • COVID-19 rebound after taking Paxlovid likely due to insufficient drug exposure
  • Novel drug combo activates natural killer cell immunity to destroy cancer cells
  • Broadly neutralizing antibodies could provide immunity against SARS-CoV-2 variants

Conferences & Events

  • New approach to treatment of deadly kidney cancer
  • SAE Media Group proudly presents the 2nd Annual Aseptic Processing Conference
  • Pharma join together to achieve new standards in digital and patient innovation for clinical transformation
  • SMi's 22nd Annual Pain Therapeutics Conference
  • SMi Group Introduces the 4th Annual Injectable Drug Delivery Conference 2022
  • SMi's 5th Annual Pharmaceutical Microbiology East Coast Conference
  • SMi's 3rd Annual AI in Drug Discovery Conference

Regulatory Affairs

  • FDA approves first systemic treatment for alopecia areata
  • FDA urges drug manufacturers to develop risk management plans to promote a dtronger, resilient drug supply chain
  • FDA limits use of Janssen COVID-19 vaccine to certain individuals
  • EMA establishes Cancer Medicines Forum with academia to optimise cancer treatments in clinical practice
  • FDA approves first generic of Symbicort to treat asthma and COPD
  1. You are here:  
  2. Home
  3. Daiichi Sankyo

About

  • Home
  • Advertise
  • Privacy
  • Cookie Preferences
  • Terms of Use
  • Contact

Top News Channels

  • Industry
  • Research
  • Regulatory

Submit Your News!

Follow / Join us

Didn't we got you connected? If not, please note the following magic buttons:
  • Facebook
  • Twitter
  • LinkedIn
  • XING
  • RSS

Digest World Pharma Newsletter

Subscribe to our weekly Digest Newsletter and stay updated on the latest World Pharma News. Subscribe now, it's free!

© World Pharma News 2022. All Rights Reserved.